Advertisement

Topics

Immune cells contribute to treatment resistance in aggressive breast cancers

12:20 EDT 21 Aug 2017 | Medical Xpress

Breast cancer remains a leading cause of cancer-related death for women in the United States. Early detection and targeted therapies have improved overall patient outcomes, but these factors also profoundly influence the wide stratification of prognoses. So-called "triple-negative" breast cancers, which lack expression of estrogen, progesterone, and human epidermal growth factor 2 (HER2) hormone receptors, cannot be targeted by existing hormonal therapies and are associated with poor patient survival. The claudin-low subtype of triple-negative breast cancer is distinguished by its exceptionally poor prognosis, as well as a substantially higher rate of immune cell infiltration within the tumor microenvironment. Though observations suggest an inverse correlation between immune infiltration and patient prognosis in breast cancer subtypes, the link has not been confirmed.

Original Article: Immune cells contribute to treatment resistance in aggressive breast cancers

NEXT ARTICLE

More From BioPortfolio on "Immune cells contribute to treatment resistance in aggressive breast cancers"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Cancer
  Bladder Cancer Brain Cancer Breast Cancer Cancer Cervical Cancer Colorectal Head & Neck Cancers Hodgkin Lymphoma Leukemia Lung Cancer Melanoma Myeloma Ovarian Cancer Pancreatic Cancer ...

Women's Health
Women's Health - key topics include breast cancer, pregnancy, menopause, stroke Follow and track Women's Health News on BioPortfolio: Women's Health News RSS Women'...